Long Non-Coding RNA- PVT1 in Ovarian Cancer as Predictors for Platinum Analogues Resistance

Abstract Background Ovarian cancer is the fifth most common type of cancer and the most common cause of death among women with gynecological malignancies. Objectives The aim of this retrospective study was to assess expression of the Lnc_PVT1 in the studied subjects. The expression of Lnc_PVT1 bioma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:QJM : An International Journal of Medicine 2021-10, Vol.114 (Supplement_1)
Hauptverfasser: Biomy, Walid Abd Almonem, Mostafa, Mohamed Yassin, EL-Khazragy, Nashwa Nagy, Ghonem, Khaled Kamal Eldein, Hewety, Amr Attia
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title QJM : An International Journal of Medicine
container_volume 114
creator Biomy, Walid Abd Almonem
Mostafa, Mohamed Yassin
EL-Khazragy, Nashwa Nagy
Ghonem, Khaled Kamal Eldein
Hewety, Amr Attia
description Abstract Background Ovarian cancer is the fifth most common type of cancer and the most common cause of death among women with gynecological malignancies. Objectives The aim of this retrospective study was to assess expression of the Lnc_PVT1 in the studied subjects. The expression of Lnc_PVT1 biomarker; was compared in ovarian cancer patients versus the non-cancerous tissue. The data normalization was tested by normality test which shows that the biomarker expression is not normally distributed; thus, a Mann Whitney statistics test for non -parametric values was applied. Our results showed a high significant difference in the expression of Lnc-PVT1 (p 
doi_str_mv 10.1093/qjmed/hcab103.002
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_qjmed_hcab103_002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/qjmed/hcab103.002</oup_id><sourcerecordid>10.1093/qjmed/hcab103.002</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1222-7686bbbfa5220f5cd096c71c1c6220f9e8db4a3a0558d1c773a4463ec12795f33</originalsourceid><addsrcrecordid>eNqNkNFOwjAUhhujiYg-gHd9AAen7bZul2RRMSFACHrjxXLWdVjCWmzBxLd3E7z36vw5-b__4iPknsGIQS7Gn9tW1-MPhRUDMQLgF2TA4hQiLnJx-ZclT67JTQhbAIhlnA3I-8zZDZ07GxWuNl1czScRXb6tGTWWLr7QG7S0QKu0pxjo0uvaqIPzgTbO0-UOD8YeWzqxuHObow50pYMJhx64JVcN7oK-O98heX16XBfTaLZ4fikms0gxznkk0yytqqrBhHNoElVDnirJFFNp_8h1VlcxCoQkyWqmpBQYx6nQHS3zpBFiSNhpV3kXgtdNufemRf9dMih7O-WvnfJsp-zsdMzDiXHH_T_qP7JLaA4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Long Non-Coding RNA- PVT1 in Ovarian Cancer as Predictors for Platinum Analogues Resistance</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Biomy, Walid Abd Almonem ; Mostafa, Mohamed Yassin ; EL-Khazragy, Nashwa Nagy ; Ghonem, Khaled Kamal Eldein ; Hewety, Amr Attia</creator><creatorcontrib>Biomy, Walid Abd Almonem ; Mostafa, Mohamed Yassin ; EL-Khazragy, Nashwa Nagy ; Ghonem, Khaled Kamal Eldein ; Hewety, Amr Attia</creatorcontrib><description>Abstract Background Ovarian cancer is the fifth most common type of cancer and the most common cause of death among women with gynecological malignancies. Objectives The aim of this retrospective study was to assess expression of the Lnc_PVT1 in the studied subjects. The expression of Lnc_PVT1 biomarker; was compared in ovarian cancer patients versus the non-cancerous tissue. The data normalization was tested by normality test which shows that the biomarker expression is not normally distributed; thus, a Mann Whitney statistics test for non -parametric values was applied. Our results showed a high significant difference in the expression of Lnc-PVT1 (p &lt; 0.01). Lnc_PVT1 expression is upregulated by 2.4 folds in ovarian cancer patients (median: 32.0; range: 11 – 92) compared to control group (median: 13.0; range: 11 – 16). Methods and Materials This is a retrospective study. Include patients with advanced epithelial ovarian cancer (stage II and IV) who received chemotherapy platinum based and taxines from 2014-2017. Setting: Clinical oncology department Ain Shams University, Egypt, Demerdash hospital. Data collection: The following information will be ANONYMOUSLY extracted from the patient medical files: age at diagnosis, presenting symptoms, laboratory investigations: (Liver function, kidney function, complete blood count &amp;tumor markers), tumor histological type, tumor FIGO stage&amp; degree of differentiation, treatment modalities, type of surgery, chemotherapy regimens (Adjuvant, Neoadjuvant or palliative), chemotherapy responsiveness or resistance, disease recurrence and disease-free period, and patients' survival. Results The current study was enrolled on 55 subjects, they classified into two subgroups. The ovarian cancer cases constitute 45 patients; samples collected from patients after diagnosis has been confirmed by histopathology based on immune-histochemical analysis as well as Computerized axial tomography (CT scan) and Magnetic resonance imaging (MRI). The cancer ovary patients were compared to ten non- malignant ovarian tissues. Table 1 illustrates the demographic and clinical data of the studied subjects. We test the normality for age; the data was normally distributed. For this reason, we represent the data in mean value and standard deviation form. Matched age and gender was observed between ovarian cancer patients and healthy control. The mean age for the studied subjects was 47.7±9.1. In our study; the Cisplatin resistant patients (n = 25) had a mean age of 46±5 compared to Cisplatin sensitive which were older (mean: 50 ±11.5). Regarding the age subgroups; the majority of the studied subjects were younger than 48 years old. The ovarian cancer patients were subcategorized into subgroups (Cisplatin sensitive/resistant). Conclusion Comparative analysis between Cisplatin sensitive and resistant ovarian cancer tissues for the Lnc_PVT1, TGF-b and Caspase-3. A high significant difference was observed by Mann- Whitney test (p = 0.001) between Cisplatin sensitive and resistant ovarian cancer patients; Cisplatin resistant tissues showed higher expression levels of the Lnc_PVT1 expression (median 20.0, range: 10 - 92) in Cisplatin sensitive ovarian tissue compared to Cisplatin resistant tissue (median: 83; range: 46-86).</description><identifier>ISSN: 1460-2725</identifier><identifier>EISSN: 1460-2393</identifier><identifier>DOI: 10.1093/qjmed/hcab103.002</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>QJM : An International Journal of Medicine, 2021-10, Vol.114 (Supplement_1)</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Biomy, Walid Abd Almonem</creatorcontrib><creatorcontrib>Mostafa, Mohamed Yassin</creatorcontrib><creatorcontrib>EL-Khazragy, Nashwa Nagy</creatorcontrib><creatorcontrib>Ghonem, Khaled Kamal Eldein</creatorcontrib><creatorcontrib>Hewety, Amr Attia</creatorcontrib><title>Long Non-Coding RNA- PVT1 in Ovarian Cancer as Predictors for Platinum Analogues Resistance</title><title>QJM : An International Journal of Medicine</title><description>Abstract Background Ovarian cancer is the fifth most common type of cancer and the most common cause of death among women with gynecological malignancies. Objectives The aim of this retrospective study was to assess expression of the Lnc_PVT1 in the studied subjects. The expression of Lnc_PVT1 biomarker; was compared in ovarian cancer patients versus the non-cancerous tissue. The data normalization was tested by normality test which shows that the biomarker expression is not normally distributed; thus, a Mann Whitney statistics test for non -parametric values was applied. Our results showed a high significant difference in the expression of Lnc-PVT1 (p &lt; 0.01). Lnc_PVT1 expression is upregulated by 2.4 folds in ovarian cancer patients (median: 32.0; range: 11 – 92) compared to control group (median: 13.0; range: 11 – 16). Methods and Materials This is a retrospective study. Include patients with advanced epithelial ovarian cancer (stage II and IV) who received chemotherapy platinum based and taxines from 2014-2017. Setting: Clinical oncology department Ain Shams University, Egypt, Demerdash hospital. Data collection: The following information will be ANONYMOUSLY extracted from the patient medical files: age at diagnosis, presenting symptoms, laboratory investigations: (Liver function, kidney function, complete blood count &amp;tumor markers), tumor histological type, tumor FIGO stage&amp; degree of differentiation, treatment modalities, type of surgery, chemotherapy regimens (Adjuvant, Neoadjuvant or palliative), chemotherapy responsiveness or resistance, disease recurrence and disease-free period, and patients' survival. Results The current study was enrolled on 55 subjects, they classified into two subgroups. The ovarian cancer cases constitute 45 patients; samples collected from patients after diagnosis has been confirmed by histopathology based on immune-histochemical analysis as well as Computerized axial tomography (CT scan) and Magnetic resonance imaging (MRI). The cancer ovary patients were compared to ten non- malignant ovarian tissues. Table 1 illustrates the demographic and clinical data of the studied subjects. We test the normality for age; the data was normally distributed. For this reason, we represent the data in mean value and standard deviation form. Matched age and gender was observed between ovarian cancer patients and healthy control. The mean age for the studied subjects was 47.7±9.1. In our study; the Cisplatin resistant patients (n = 25) had a mean age of 46±5 compared to Cisplatin sensitive which were older (mean: 50 ±11.5). Regarding the age subgroups; the majority of the studied subjects were younger than 48 years old. The ovarian cancer patients were subcategorized into subgroups (Cisplatin sensitive/resistant). Conclusion Comparative analysis between Cisplatin sensitive and resistant ovarian cancer tissues for the Lnc_PVT1, TGF-b and Caspase-3. A high significant difference was observed by Mann- Whitney test (p = 0.001) between Cisplatin sensitive and resistant ovarian cancer patients; Cisplatin resistant tissues showed higher expression levels of the Lnc_PVT1 expression (median 20.0, range: 10 - 92) in Cisplatin sensitive ovarian tissue compared to Cisplatin resistant tissue (median: 83; range: 46-86).</description><issn>1460-2725</issn><issn>1460-2393</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqNkNFOwjAUhhujiYg-gHd9AAen7bZul2RRMSFACHrjxXLWdVjCWmzBxLd3E7z36vw5-b__4iPknsGIQS7Gn9tW1-MPhRUDMQLgF2TA4hQiLnJx-ZclT67JTQhbAIhlnA3I-8zZDZ07GxWuNl1czScRXb6tGTWWLr7QG7S0QKu0pxjo0uvaqIPzgTbO0-UOD8YeWzqxuHObow50pYMJhx64JVcN7oK-O98heX16XBfTaLZ4fikms0gxznkk0yytqqrBhHNoElVDnirJFFNp_8h1VlcxCoQkyWqmpBQYx6nQHS3zpBFiSNhpV3kXgtdNufemRf9dMih7O-WvnfJsp-zsdMzDiXHH_T_qP7JLaA4</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Biomy, Walid Abd Almonem</creator><creator>Mostafa, Mohamed Yassin</creator><creator>EL-Khazragy, Nashwa Nagy</creator><creator>Ghonem, Khaled Kamal Eldein</creator><creator>Hewety, Amr Attia</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20211001</creationdate><title>Long Non-Coding RNA- PVT1 in Ovarian Cancer as Predictors for Platinum Analogues Resistance</title><author>Biomy, Walid Abd Almonem ; Mostafa, Mohamed Yassin ; EL-Khazragy, Nashwa Nagy ; Ghonem, Khaled Kamal Eldein ; Hewety, Amr Attia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1222-7686bbbfa5220f5cd096c71c1c6220f9e8db4a3a0558d1c773a4463ec12795f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Biomy, Walid Abd Almonem</creatorcontrib><creatorcontrib>Mostafa, Mohamed Yassin</creatorcontrib><creatorcontrib>EL-Khazragy, Nashwa Nagy</creatorcontrib><creatorcontrib>Ghonem, Khaled Kamal Eldein</creatorcontrib><creatorcontrib>Hewety, Amr Attia</creatorcontrib><collection>CrossRef</collection><jtitle>QJM : An International Journal of Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Biomy, Walid Abd Almonem</au><au>Mostafa, Mohamed Yassin</au><au>EL-Khazragy, Nashwa Nagy</au><au>Ghonem, Khaled Kamal Eldein</au><au>Hewety, Amr Attia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long Non-Coding RNA- PVT1 in Ovarian Cancer as Predictors for Platinum Analogues Resistance</atitle><jtitle>QJM : An International Journal of Medicine</jtitle><date>2021-10-01</date><risdate>2021</risdate><volume>114</volume><issue>Supplement_1</issue><issn>1460-2725</issn><eissn>1460-2393</eissn><abstract>Abstract Background Ovarian cancer is the fifth most common type of cancer and the most common cause of death among women with gynecological malignancies. Objectives The aim of this retrospective study was to assess expression of the Lnc_PVT1 in the studied subjects. The expression of Lnc_PVT1 biomarker; was compared in ovarian cancer patients versus the non-cancerous tissue. The data normalization was tested by normality test which shows that the biomarker expression is not normally distributed; thus, a Mann Whitney statistics test for non -parametric values was applied. Our results showed a high significant difference in the expression of Lnc-PVT1 (p &lt; 0.01). Lnc_PVT1 expression is upregulated by 2.4 folds in ovarian cancer patients (median: 32.0; range: 11 – 92) compared to control group (median: 13.0; range: 11 – 16). Methods and Materials This is a retrospective study. Include patients with advanced epithelial ovarian cancer (stage II and IV) who received chemotherapy platinum based and taxines from 2014-2017. Setting: Clinical oncology department Ain Shams University, Egypt, Demerdash hospital. Data collection: The following information will be ANONYMOUSLY extracted from the patient medical files: age at diagnosis, presenting symptoms, laboratory investigations: (Liver function, kidney function, complete blood count &amp;tumor markers), tumor histological type, tumor FIGO stage&amp; degree of differentiation, treatment modalities, type of surgery, chemotherapy regimens (Adjuvant, Neoadjuvant or palliative), chemotherapy responsiveness or resistance, disease recurrence and disease-free period, and patients' survival. Results The current study was enrolled on 55 subjects, they classified into two subgroups. The ovarian cancer cases constitute 45 patients; samples collected from patients after diagnosis has been confirmed by histopathology based on immune-histochemical analysis as well as Computerized axial tomography (CT scan) and Magnetic resonance imaging (MRI). The cancer ovary patients were compared to ten non- malignant ovarian tissues. Table 1 illustrates the demographic and clinical data of the studied subjects. We test the normality for age; the data was normally distributed. For this reason, we represent the data in mean value and standard deviation form. Matched age and gender was observed between ovarian cancer patients and healthy control. The mean age for the studied subjects was 47.7±9.1. In our study; the Cisplatin resistant patients (n = 25) had a mean age of 46±5 compared to Cisplatin sensitive which were older (mean: 50 ±11.5). Regarding the age subgroups; the majority of the studied subjects were younger than 48 years old. The ovarian cancer patients were subcategorized into subgroups (Cisplatin sensitive/resistant). Conclusion Comparative analysis between Cisplatin sensitive and resistant ovarian cancer tissues for the Lnc_PVT1, TGF-b and Caspase-3. A high significant difference was observed by Mann- Whitney test (p = 0.001) between Cisplatin sensitive and resistant ovarian cancer patients; Cisplatin resistant tissues showed higher expression levels of the Lnc_PVT1 expression (median 20.0, range: 10 - 92) in Cisplatin sensitive ovarian tissue compared to Cisplatin resistant tissue (median: 83; range: 46-86).</abstract><pub>Oxford University Press</pub><doi>10.1093/qjmed/hcab103.002</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1460-2725
ispartof QJM : An International Journal of Medicine, 2021-10, Vol.114 (Supplement_1)
issn 1460-2725
1460-2393
language eng
recordid cdi_crossref_primary_10_1093_qjmed_hcab103_002
source Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Long Non-Coding RNA- PVT1 in Ovarian Cancer as Predictors for Platinum Analogues Resistance
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A05%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%20Non-Coding%20RNA-%20PVT1%20in%20Ovarian%20Cancer%20as%20Predictors%20for%20Platinum%20Analogues%20Resistance&rft.jtitle=QJM%20:%20An%20International%20Journal%20of%20Medicine&rft.au=Biomy,%20Walid%20Abd%20Almonem&rft.date=2021-10-01&rft.volume=114&rft.issue=Supplement_1&rft.issn=1460-2725&rft.eissn=1460-2393&rft_id=info:doi/10.1093/qjmed/hcab103.002&rft_dat=%3Coup_cross%3E10.1093/qjmed/hcab103.002%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/qjmed/hcab103.002&rfr_iscdi=true